T
Healthcare and Life Sciences
Tausif Qudsi
Answer 1
Views 510
1

PD-1/PDL-1 Inhibitor Market

What is the average total number or percentage of Mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer patients?

Oncology

immunoncology

Therapeutics

cancer